October 01, 2016 6:23 PM ET


Company Overview of Perosphere Inc.

Company Overview

Perosphere Inc., a specialty pharmaceutical company, focuses on developing rescue medications. Its products include ciraparantag (PER977) is an intravenously administered small synthetic water soluble new molecular entity for use as a reversal agent for anticoagulants, including heparins, as well as direct oral anticoagulants, allowing re-establishment of a normal blood coagulation state when clinically indicated; and point-of-care coagulometer, a hand-held anticoagulant monitoring diagnostic device for measuring or monitoring the activity of anticoagulants and their corresponding reversal agents across various drug classes. The company’s products also comprise PER1080, a formulation of a th...

20 Kenosia Avenue

Danbury, CT 06810

United States

Founded in 2011



Key Executives for Perosphere Inc.

Founder, Chairman, Chief Executive Officer and President
Age: 78
Founder, Chief Scientific Officer and Senior Executive Vice President
Founder and Senior Executive Vice President of Research
Founder and Member of Advisory Board
Chief Financial Officer, Executive Vice President of Finance and Treasurer
Compensation as of Fiscal Year 2016.

Perosphere Inc. Key Developments

Perosphere Inc. Receives FDA Fast Track Designation for Investigational Anticoagulant Reversal Agent PER977

Perosphere Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for PER977, an investigational anticoagulant reversal agent. The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. An important feature of Fast Track is that the FDA may grant frequent and expedited interactions to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. Fast Track also offers the opportunity for the FDA to consider a "rolling review" of completed sections of the New Drug Application (NDA) before the complete application is submitted.

Perosphere Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015

Perosphere Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Perosphere Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Perosphere Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Private Placement
October 8, 2015

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Perosphere Inc., please visit www.perosphere.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.